Biogen continues to expect a gradual launch of the company’s Byooviz (ranibizumab-nuna) biosimilar, following market entry in June, “with more meaningful revenue contribution starting in 2023.”
The US-based biotech’s prediction came as it admitted that its global biosimilar sales for 2022 would not hit the heights of 2021 ($831m), amid sustained negative
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?